Page 30 - Clinical Development News Today

/PRNewswire/ -- Bold Therapeutics, a clinical-stage biopharmaceutical company at the forefront of developing innovative metallotherapeutics, has announced that...

　Osaka, Japan, April 5, 2024 - Ono Pharmaceutical Co., Ltd. announced that it has decided changes of the Board of Directors, Audit & Supervisory Board Members and Corporate Officers at the...

Dublin, April 05, 2024 (GLOBE NEWSWIRE) -- The "NOURIANZ Market Size, Forecast, and Market Insight - 2032" report has been added to ResearchAndMarkets.com's offering.This report provides comprehensive insights about NOURIANZ for Parkinson's disease in the US and Japan. A detailed picture of the NOURIANZ for Parkinson's disease in the United States and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the NOURIANZ for Pa...

Merck announced today that it has launched a phase 3 clinical trial evaluating its MK-1084 in combination with Keytruda for the first-line treatment of selected patients with metastatic non-small...

In February, Trialbee announced its Omnichannel Network partnership with Massive Bio, a global leader in AI-enabled patient journey mapping platform to help better connect cancer patients with their oncologists/hematologists in clinical trials.

Precision oncology innovator SimBioSys and General Inception have joined forces in a strategic partnership aimed at revolutionizing cancer drug development.

Dr Laura Trotta joined CluePoints in 2015 and moved into her current role as vice president of research in January 2022, where she leads a team of research scientists responsible for developing new statistical and machine learning algorithms to assess the quality of clinical trial data.

Molecure S.A., a leading biotechnology company focused on drug discovery and development, has unveiled its annual report for 2023 at the start of the new financial year.

Beacon Biosignals made waves in the healthcare tech sector today with the announcement of FDA 510(k) clearance for a progressive machine learning software designed to change the analysis of sleep patterns.

Bora Pharmaceuticals Co., Ltd. yesterday (April 1) finalized the acquisition of Upsher-Smith Laboratories, Inc., a leading generics manufacturer based in Minnesota, U.S., from its previous owners, Sawai Group Holdings and Sumitomo Corporation of Americas.